Correction: Heparanase promotes glioma progression and is inversely correlated with patient survival (Molecular Cancer Research (2016) 14 (1243-1253) DOI: 10.1158/1541-7786.MCR-16-0223);Heparanase promotes glioma progression and is inversely correlated with patient survival

Molecular Cancer Research

Volumn 14, Issue 12, 2016, Pages 1243-1253

  Kundu, Soumi ^a   Xiong, Anqi ^a   Spyrou, Argyris ^a   Wicher, Grzegorz ^a   Marinescu, Voichita D ^a   Edqvist, Per Henrik D ^a   Zhang, Lei ^a   Essand, Magnus ^a   Dimberg, Anna ^a   Smits, Anja ^a   Ilan, Neta ^b   Vlodavsky, Israel ^b   Li, Jin Ping ^a   Forsberg Nilsson, Karin ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN ENZYME; HEPARANASE; HEPARANASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PG 545; PROTEIN KINASE B; UNCLASSIFIED DRUG; BETA GLUCURONIDASE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVOR; CELL COUNT; CELL PROLIFERATION; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LUMINESCENCE; MICROGLIA; MONOCYTE; MOUSE; NONHUMAN; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; BRAIN TUMOR; CELL NUCLEUS; CELL SURVIVAL; DISEASE COURSE; GENE EXPRESSION REGULATION; GLIOBLASTOMA; METABOLISM; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR CELL LINE; UPREGULATION;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; GLUCURONIDASE; HUMANS; MICE; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; UP-REGULATION;

EID: 85003876000     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-18-0186     Document Type: Erratum

References (48)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
2. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
3. Goldshmidt O, Nadav L, Aingorn H, Irit C, Feinstein N, Ilan N, et al. Human heparanase is localized within lysosomes in a stable form. Exp Cell Res 2002;281:50-62.
4. Nakada M, Nakada S, Demuth T, Tran NL, Hoelzinger DB, Berens ME. Molecular targets of glioma invasion. Cell Mol Life Sci 2007;64:458-78.
5. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H. The brain tumor microenvironment. Glia 2011;59:1169-80.
6. Bellail AC, Hunter SB, Brat DJ, Tan C, Van Meir EG. Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol 2004;36:1046-69.
7. Xiong A, Kundu S, Forsberg-Nilsson K. Heparan sulfate in the regulation of neural differentiation and glioma development. FEBS J 2014;281:4993-5008.
8. Wade A, Robinson AE, Engler JR, Petritsch C, James CD, Phillips JJ. Proteoglycans and their roles in brain cancer. FEBS J 2013;280:2399-417.
9. Esko JD, Lindahl U. Molecular diversity of heparan sulfate. J Clin Invest 2001;108:169-73.
10. Habuchi H, Habuchi O, Kimata K. Sulfation pattern in glycosaminoglycan: Does it have a code? Glycoconj J 2004;21:47-52.
11. Vlodavsky I, Beckhove P, Lerner I, Pisano C, Meirovitz A, Ilan N, et al. Significance of heparanase in cancer and inflammation. Cancer Microenviron 2012;5:115-32.
12. Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, Parish CR. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med 1999;5:803-9.
13. Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli R, et al. Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis. Nat Med 1999;5:793-802.
14. Koliopanos A, Friess H, Kleeff J, Shi X, Liao Q, Pecker I, et al. Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res 2001;61:4655-9.
15. Ben-Izhak O, Kaplan-Cohen V, Ilan N, Gan S, Vlodavsky I, Nagler R. Heparanase expression in malignant salivary gland tumors inversely correlates with long-term survival. Neoplasia 2006;8:879-84.
16. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006;38:2018-39.
17. Szatmari T, Lumniczky K, Desaknai S, Trajcevski S, Hidvegi EJ, Hamada H, et al. Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci 2006;97:546-53.
18. Xie Y, Bergstrom T, Jiang Y, Johansson P, Marinescu VD, Lindberg N, et al. The human glioblastoma cell culture resource: Validated cell models representing all molecular subtypes. EBioMedicine 2015;2:1351-63.
19. Zetser A, Levy-Adam F, Kaplan V, Gingis-Velitski S, Bashenko Y, Schubert S, et al. Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci 2004;117(Pt 11):2249-58.
20. Bergstrom T, Holmqvist K, Tararuk T, Johansson S, Forsberg-Nilsson K. Developmentally regulated collagen/integrin interactions confer adhesive properties to early postnatal neural stem cells. Biochim Biophys Acta 2014;1840:2526-32.
21. Zhang L, Kundu S, Feenstra T, Li X, Jin C, Laaniste L, et al. Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas. Sci Signal 2015;8:ra125.
22. Purushothaman A, Chen L, Yang Y, Sanderson RD. Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem 2008;283:32628-36.
23. Jin C, Yu D, Hillerdal V, Wallgren A, Karlsson-Parra A, Essand M. Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors. Mol Ther Methods Clin Dev 2014;1:14001.
24. Zcharia E, Metzger S, Chajek-Shaul T, Aingorn H, Elkin M, Friedmann Y, et al. Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior. FASEB J 2004;18:252-63.
25. Zcharia E, Jia J, Zhang X, Baraz L, Lindahl U, Peretz T, et al. Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases. PLoS One 2009;4:e5181.
26. Polajeva J, Bergstrom T, Edqvist PH, Lundequist A, Sjosten A, Nilsson G, et al. Glioma-derived macrophage migration inhibitory factor (MIF) promotes mast cell recruitment in a STAT5-dependent manner. Mol Oncol 2014;8:50-8.
27. Kampf C, Olsson I, Ryberg U, Sjostedt E, Ponten F. Production of tissue microarrays, immunohistochemistry staining and digitalization within the human protein atlas. J Vis Exp 2012.
28. Hammond E, Handley P, Dredge K, Bytheway I. Mechanisms of heparanase inhibition by the heparan sulfate mimetic PG545 and three structural analogues. FEBS Open Bio 2013;3:346-51.
29. Schubert SY, Ilan N, Shushy M, Ben-Izhak O, Vlodavsky I, Goldshmidt O. Human heparanase nuclear localization and enzymatic activity. Lab Invest 2004;84:535-44.
30. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401-4.
31. Network. CGAR. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
32. Dredge K, Hammond E, Handley P, Gonda TJ, Smith MT, Vincent C, et al. PG545, a dual heparanase and angiogenesis inhibitor, induces potent antitumour and anti-metastatic efficacy in preclinical models. Br J Cancer 2011;104:635-42.
33. Ferro V, Liu L, Johnstone KD, Wimmer N, Karoli T, Handley P, et al. Discovery of PG545: A highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis. J Med Chem 2012;55:3804-13.
34. Jung DB, Yun M, Kim EO, Kim J, Kim B, Jung JH, et al. The heparan sulfate mimetic PG545 interferes with Wnt/beta-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine. Oncotarget 2015;6:4992-5004.
35. Ben-Zaken O, Gingis-Velitski S, Vlodavsky I, Ilan N. Heparanase induces Akt phosphorylation via a lipid raft receptor. Biochem Biophys Res Commun 2007;361:829-34.
36. Riaz A, Ilan N, Vlodavsky I, Li JP, Johansson S. Characterization of heparanase-induced phosphatidylinositol 3-kinase-AKT activation and its integrin dependence. J Biol Chem 2013;288:12366-75.
37. Silver DJ, Siebzehnrubl FA, Schildts MJ, Yachnis AT, Smith GM, Smith AA, et al. Chondroitin sulfate proteoglycans potently inhibit invasion and serve as a central organizer of the brain tumor microenvironment. J Neurosci 2013;33:15603-17.
38. Villeneuve J, Tremblay P, Vallieres L. Tumor necrosis factor reduces brain tumor growth by enhancing macrophage recruitment and microcyst formation. Cancer Res 2005;65:3928-36.
39. Sarkar S, Doring A, Zemp FJ, Silva C, Lun X, Wang X, et al. Therapeutic activation of macrophages and microglia to suppress brain tumor-initiating cells. Nat Neurosci 2014;17:46-55.
40. O'Callaghan P, Li JP, Lannfelt L, Lindahl U, Zhang X. Microglial heparan sulfate proteoglycans facilitate the cluster-of-differentiation 14 (CD14)/toll-like receptor 4 (TLR4)-dependent inflammatoryresponse. J Biol Chem 2015;290:14904-14.
41. Ueno Y, Yamamoto M, Vlodavsky I, Pecker I, Ohshima K, Fukushima T. Decreased expression of heparanase in glioblastoma multiforme. J Neurosurg 2005;102:513-21.
42. Hong X, Nelson KK, deCarvalho AC, Kalkanis SN. Heparanase expression of glioma in human and animal models. J Neurosurg 2010;113:261-9.
43. Watanabe A, Mabuchi T, Satoh E, Furuya K, Zhang L, Maeda S, et al. Expression of syndecans, a heparan sulfate proteoglycan, in malignant gliomas: Participation of nuclear factor-kappaB in upregulation of syndecan-1 expression. J Neurooncol 2006;77:25-32.
44. Ramani VC, Purushothaman A, Stewart MD, Thompson CA, Vlodavsky I, Au JL, et al. The heparanase/syndecan-1 axis in cancer: Mechanisms and therapies. FEBS J 2013;280:2294-306.
45. Sato T, Yamaguchi A, Goi T, Hirono Y, Takeuchi K, Katayama K, et al. Heparanase expression in human colorectal cancer and its relationship to tumor angiogenesis, hematogenous metastasis, and prognosis. J Surg Oncol 2004;87:174-81.
46. Kim AW, Xu X, Hollinger EF, Gattuso P, Godellas CV, Prinz RA. Human heparanase-1 gene expression in pancreatic adenocarcinoma. J Gastrointest Surg 2002;6:167-72.
47. Cohen E, Doweck I, Naroditsky I, Ben-Izhak O, Kremer R, Best LA, et al. Heparanase is overexpressed in lung cancer and correlates inversely with patient survival. Cancer 2008;113:1004-11.
48. Fedarko NS, Conrad HE. A unique heparan sulfate in the nuclei of hepatocytes: Structural changes with the growth state of the cells. J Cell Biol 1986;102:587-99.